Industry support of CME declines 17%

Share this article:
Total commercial support of accredited CME fell 17% to $856 million in 2009, according to ACCME's annual report—marking its second straight year of double-digit declines on a percentage basis.

For 2007, ACCME data showed commercial support increasing 1%. Sandwiched between 2008, when industry grants slid 14% to $1 billion, and a decade of sizable gains before it, 2007 proved to be the peak. The 2009 total also marks the first time since 2003 that industry funding dipped below $1 billion.

The number of physicians and non-physicians participating in CME stayed fairly flat in 2009, rising just 1% and 3%, respectively. The steady attendance figures—10.7 million doctors and 6.8 million non-physicians—proved to be a lone bright spot.

Total income reported by accredited providers fell 7.6% to $2.2 billion, while total expenses also decreased 11.9% to $1.7 billion. Providers actually faced higher fees and administrative work last year as they incorporated new transparency and measurement policies. The lower expenses could partly reflect attrition among ACCME-accredited providers: there are now 707 vs. 725 in 2008.

The number of certified CME activities and the number of hours of CME logged were also down in 2009, with activities declining 5.8% to 95,062 and hours plunging 10.4% to 689,768.

Industry grants, now accounting for 39% of total CME income vs. 56% in 2008, have taken a hit due to overall budget cuts by drug and device companies and the extreme scrutiny placed on industry-supported CME due to perceived bias.

Those hardest hit by the decline in commercial support were professional associations, which saw total income fall nearly 25%, followed by MECCs, which experienced a 21% drop.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.